drugset / Trial / NCT06942143
An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors
Phase 1
Recruiting
15 enrolled
Guangzhou FineImmune Biotechnology Co., LTD.
Sun Yat-Sen University Cancer Center · collab
NaSingle-groupOpen-labelTreatment
Summary
This study was a phase I safety and tolerability clinical trial conducted in a single-center, open-label, 3+3 design with dose escalation.
Timeline
- Start
- 2025-05-22
- Primary completion
- 2027-04-25
- Completion
- 2027-06-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Super1 TCR-T | Cell therapy | — | — |